Goldman Sachs initiates Nurix stock with Buy rating, $182 price target

Goldman Sachs initiated coverage on Nurix (NASDAQ:NRIX) with a "Buy" rating and a $182.00 price target, citing significant enthusiasm for its Crenessity drug, which is expected to offset future Ingrezza headwinds, and a belief that current consensus estimates for Crenessity are overly conservative. This bullish outlook follows Nurix's strong Q2 FY25 financial performance, where revenue of $44.1 million significantly exceeded projections and the net loss of -$0.52 per share beat analyst expectations. The initiation, alongside Stifel's reiterated "Buy" rating and $4.5 billion peak sales projection for bexobrutideg, underscores significant analyst confidence in Nurix's pipeline and growth prospects.

Analysis

Goldman Sachs has initiated coverage on Nurix Therapeutics (NRIX) with a "Buy" rating and a $182 price target, signaling substantial perceived upside from its current trading level of $13.18. The investment bank's thesis hinges on the commercial potential of Nurix's pipeline drug, Crenessity, for which key opinion leader checks reveal significant enthusiasm. Goldman's analysis suggests current consensus estimates for Crenessity are overly conservative and that its launch will offset potential future headwinds for Ingrezza. This optimistic outlook is supported by Nurix's recent fiscal second-quarter performance, where the company reported revenue of $44.1 million, vastly exceeding the $17.5 million consensus, driven by license and milestone payments from partners Sanofi and Gilead. The quarterly net loss of $0.52 per share also beat expectations of a $0.74 loss. This financial outperformance coincides with another bullish analyst action from Stifel, which reiterated its "Buy" rating with a $35 target, projecting peak sales of $4.5 billion for another pipeline candidate, bexobrutideg. Despite these positive catalysts, the company's R&D expenses rose to $78.1 million and its cash position declined to $485.8 million, highlighting a significant cash burn rate. The stock's high beta of 2.15 underscores the inherent volatility associated with a clinical-stage biotechnology firm.

Key Decisions for Investors

• Given the strong "Buy" ratings from both Goldman Sachs and Stifel, backed by significant Q2 revenue and earnings beats, investors may view the current valuation as a compelling entry point for a high-growth opportunity.
• The investment case is heavily reliant on future clinical and commercial success; therefore, investors should closely monitor trial progress and data readouts for key pipeline assets Crenessity and bexobrutideg, as these are the primary drivers of the bullish price targets.
• Investors must consider the financial risks, including the notable cash burn rate and the stock's high volatility (beta of 2.15), and should track the company's ability to manage its cash runway and secure future partnership milestones to fund development.